Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and e...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

MorganHoratio Jul. 2 at 10:34 PM

One of the strongest sectors outside of AI right now is Biotech. Immunology $ORKA Oruka Therapeutics $DNTH Dianthus Therapeutics $APGE Apogee Therapeutics $IMVT Immunovant $KNSA Kiniksa Pharmaceuticals Tech is rocky, and smart money is hunting for growth outside of AI. The verdict? Biotech’s Immunology & Inflammation (I&I) sector is absolutely ripping! The momentum here is insane: APGE just clocked an all-time high, DNTH launched its Phase 3 trial, smashing 52-week highs, and ORKA, IMVT, and KNSA are seeing massive inflows. I&I is starting to look like the next GLP-1 style mega-trend with its massive addressable markets and high patient stickiness. Once clinical data hits, it’s off to the moon. Can I&I outpace AI for the rest of the year? Which ticker is your top play: ORKA, DNTH, APGE, IMVT, or KNSA? Drop your picks below!

1 · Reply

TradeSun Jul. 2 at 1:25 PM

$ALT Regarding the question about growing short interest: I’ve noticed several times that short interest increased significantly and kept rising right up until the buyout of certain biotech companies. I asked ChatGPT to list the major biotech buyouts in 2026. The results are $TECH, $APGE, and $FOLD. Interestingly, all of them showed elevated or growing short interest leading up to the acquisition announcement. 👇

0 · Reply

Quantumup Jul. 1 at 1:37 PM

UBS⬆️ $ORKA to $130 from $100, reiterated Buy and said, We continue to like ORKA into the H2 28-week efficacy data readout and initial durability data. $APGE - $ABBV JNJ - PTGX ALMS TAK UBS added—We believe the H2 data will likely show higher efficacy than the 16-week dataset and Skyrizi too at the same 28-week timepoint, supported by numerous psoriasis studies that generally demonstrate improving efficacy over time. While the stock has had a significant run-up, we still view it as undervalued at a ~$8-9B market cap* relative to comps including RXDX and APGE (both were acquired for $11B), particularly given its peak sales potential in a large $30 - 50B+ I&I market and potentially two differentiated assets: a long-acting IL-23 and a long-acting IL-17 A/F. We see additional 20-40%+ upside into the H2/26 data update and potentially more upside in 2027, with multiple Phase II datasets expected and the story becoming increasingly de-risked. Reiterate BUY and raise our PT to $130.

0 · Reply

JFais Jun. 30 at 3:24 PM

Coffee at the Close replay $XBI https://youtu.be/IkukIiodfsU?si=gXmXi96Oo9KezLLa A few topics covered: -How we respond to biotech "gut punches" / negative news (choose logic over emotion) $OMER -Regulatory reversals & impact on sentiment $QURE -How @JoseRestonVA views selling pressure (examples with $APGE and $BHVN 1.0) -Our💡moment (less is more vs overtrading) -Importance of waiting for the right pitches vs chasing at highs

1 · Reply

lostifm Jun. 27 at 7:17 AM

$EVMN tic toc 👀 Loaded shares today. Especially with $APGE buyout, positive results will really skyrocket

0 · Reply

bden21 Jun. 27 at 5:40 AM

$APGE so, no bidding wars!!! Is it possible we get a better offer?

0 · Reply

topstockalerts Jun. 27 at 2:15 AM

Healthcare stocks attracted strong investor demand this week as money rotated out of technology shares, pushing AbbVie, Eli Lilly and Johnson & Johnson to record closing highs. The sector benefited from its defensive characteristics and confidence in the long-term growth prospects of leading pharmaceutical companies. AbbVie's shares received an additional boost after the company announced plans to acquire Apogee Therapeutics, strengthening its drug development pipeline. According to RBC Capital Markets, AbbVie, Eli Lilly and Johnson & Johnson have largely avoided the operational setbacks that forced several competitors to restructure, while making strategic acquisitions that enhance future growth opportunities. Other biopharmaceutical companies, including Regeneron, Sanofi, Moderna and Absci, also advanced, lifting healthcare-focused ETFs as investors sought stability amid weakness in technology stocks and growing uncertainty around AI-related valuations. $ABBV $APGE $REGN $SNY $LLY

0 · Reply

SellasgpsCurativeBAT11 Jun. 26 at 3:49 PM

$SLS $APGE Biotech M&A season is HERE. The Apogee Therapeutics deal turned the volume all the way up. Big pharma is officially back in buy mode. Wall Street is actively hunting. Analysts have their eyes on the next wave of takeover targets. Apogee Therapeutics changed the game. AbbVie paid $10.9B for a pre-commercial immunology biotech. Big pharma shows that level of conviction. Investors immediately start scanning for the next company with: - Strong Phase 2/3 data - Clean balance sheets - Undervalued market caps - Assets in immunology, inflammation, or rare disease - Strategic fit for pharma facing patent cliffs. SLS Next up. 🙏✌️❤️‍🩹

0 · Reply

EluyE Jun. 25 at 3:39 PM

$APGE This stock is the luckiest on the street..Had the deal happened just a couple of days ago later that it did, it would have been sub 100 for sure!! Can’t they renegotiate this deal?

1 · Reply

OnlyFibs Jun. 24 at 8:16 PM

RECAP 6/24 +Pos Comments: $PAC + Itau BBA $MHO + Freedom Broker RECAP 6/24 -Neg Comments: $APGE - Stifel $MCHP - J capital

0 · Reply

Apogee Therapeutics Proxy statement: Proxy filing

Jun 26, 2026, 2:39 PM EDT - 8 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 8 days ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 25, 2026, 11:31 AM EDT - 9 days ago

Biotech ETF Index Surges 10% After Rebalance

ALKS DFTX DYN KLRA KYMR MANE MIRM

Jun 24, 2026, 12:51 PM EDT - 10 days ago

AbbVie's $11 Billion Immunology Bet

ABBV

2026-06-24T13:35:15.000Z - 10 days ago

Apogee Therapeutics downgraded to Hold from Buy at Stifel

2026-06-24T09:00:21.000Z - 10 days ago

Apogee Therapeutics downgraded to Neutral from Outperform at Mizuho

2026-06-23T21:45:11.000Z - 10 days ago

Apogee Therapeutics downgraded to Hold from Buy at TD Cowen

ABBV

2026-06-23T12:26:54.000Z - 11 days ago

Apogee Therapeutics downgraded to Neutral from Buy at Guggenheim

2026-06-23T12:22:00.000Z - 11 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

ABBV

2026-06-23T11:29:50.000Z - 11 days ago

Apogee Therapeutics moved to No Rating at BofA

ABBV

2026-06-23T11:28:00.000Z - 11 days ago

Apogee Therapeutics downgraded to Neutral from Buy at Citi

2026-06-23T09:26:30.000Z - 11 days ago

Apogee Therapeutics downgraded to Neutral from Buy at UBS

2026-06-22T21:55:09.000Z - 11 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

ABBV EVMN

2026-06-22T19:45:24.000Z - 11 days ago

Apogee Therapeutics downgraded to Hold from Buy at Deutsche Bank

2026-06-22T16:11:00.000Z - 12 days ago

Apogee Therapeutics rises 46.8%

2026-06-22T15:55:21.000Z - 12 days ago

Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum

2026-06-22T15:00:08.000Z - 12 days ago

Apogee Therapeutics downgraded to Neutral from Outperform at Wedbush

Jun 22, 2026, 10:30 AM EDT - 12 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

ABBV CRDO MU

Jun 22, 2026, 10:15 AM EDT - 12 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

ABBV

2026-06-22T14:11:39.000Z - 12 days ago

Apogee Therapeutics rises 46.7%

2026-06-22T13:14:21.000Z - 12 days ago

Apogee Therapeutics downgraded to Hold from Buy at Canaccord

2026-06-22T12:24:03.000Z - 12 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

ABBV REGN

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Apogee Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 7:42 AM EDT - 12 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

ABBV

2026-06-22T11:15:52.000Z - 12 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

ABBV

Jun 22, 2026, 7:06 AM EDT - 12 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

ABBV

Jun 22, 2026, 7:04 AM EDT - 12 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

ABBV

Jun 22, 2026, 7:00 AM EDT - 12 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

ABBV

Jun 22, 2026, 5:56 AM EDT - 12 days ago

Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today's Market

INTC MU SPCX

Jun 20, 2026, 12:11 PM EDT - 14 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

ABBV

Jun 19, 2026, 11:17 AM EDT - 15 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

ABBV

Jun 10, 2026, 9:20 AM EDT - 24 days ago

Apogee Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:00 AM EDT - 25 days ago

Apogee Therapeutics Transcript: AGM 2026

Jun 3, 2026, 11:40 AM EDT - 4 weeks ago

Apogee Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:01 PM EDT - 5 weeks ago

Apogee Therapeutics to Participate in Upcoming June Conferences

May 27, 2026, 8:49 AM EDT - 5 weeks ago

Apogee secures up to $1.3 billion from Blackstone to advance eczema drug

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Apogee Therapeutics Transcript: Study result

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Apogee Therapeutics Slides: Study result

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Apogee Therapeutics Press release: Study result

May 27, 2026, 6:31 AM EDT - 5 weeks ago

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

May 27, 2026, 6:30 AM EDT - 5 weeks ago

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

May 26, 2026, 4:01 PM EDT - 5 weeks ago

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Apogee Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Apogee Therapeutics Quarterly report: Q1 2026

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Apogee Therapeutics Proxy statement: Proxy filing

Mar 26, 2026, 4:01 PM EDT - 3 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Mar 24, 2026, 9:53 PM EDT - 3 months ago

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Mar 23, 2026, 4:01 PM EDT - 3 months ago

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Apogee Therapeutics Transcript: Study result

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Apogee Therapeutics Press release: Study result

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Apogee Therapeutics Slides: Study result

Mar 23, 2026, 6:30 AM EDT - 3 months ago

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

Mar 22, 2026, 7:51 PM EDT - 3 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Mar 3, 2026, 9:10 AM EST - 4 months ago

Apogee Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 4 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 4 months ago

Apogee Therapeutics Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 4 months ago

Apogee Therapeutics Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 4 months ago

Apogee Therapeutics Slides: Corporate presentation

Feb 24, 2026, 7:30 AM EST - 4 months ago

Apogee Therapeutics to Participate in Upcoming March Conferences

Feb 12, 2026, 2:00 PM EST - 5 months ago

Apogee Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 5 months ago

Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 6, 2026, 8:00 AM EST - 6 months ago

Apogee Therapeutics Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Apogee Therapeutics Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 6 months ago

Apogee Therapeutics Slides: Study Result

Jan 6, 2026, 6:00 AM EST - 6 months ago

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Jan 5, 2026, 4:01 PM EST - 6 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

Dec 3, 2025, 9:45 AM EST - 7 months ago

Apogee Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Nov 19, 2025, 10:00 AM EST - 8 months ago

Apogee Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 12:30 PM EST - 8 months ago

Apogee Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 11:20 AM EST - 8 months ago

Apogee Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 1:30 PM EST - 8 months ago

Apogee Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:10 AM EST - 8 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 7:00 AM EST - 8 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Nov 10, 2025, 7:00 AM EST - 8 months ago

Apogee Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Apogee Therapeutics Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 8 months ago

Apogee Therapeutics Slides: Corporate Presentation

Nov 3, 2025, 7:30 AM EST - 8 months ago

Apogee Therapeutics to Participate in Upcoming Conferences

Oct 10, 2025, 4:01 PM EDT - 9 months ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Oct 8, 2025, 9:52 PM EDT - 9 months ago

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Oct 8, 2025, 4:01 PM EDT - 9 months ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Sep 16, 2025, 11:30 AM EDT - 10 months ago

Apogee Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 11, 2025, 7:30 AM EDT - 10 months ago

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

Sep 3, 2025, 7:30 AM EDT - 10 months ago

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Apogee Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Apogee Therapeutics Earnings release: Q2 2025

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Transcript: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Press release: Study Result

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Study Result

Jul 7, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Corporate Presentation

Jul 7, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Jul 6, 2025, 6:00 PM EDT - 1 year ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Jun 5, 2025, 10:30 AM EDT - 1 year ago

Apogee Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 13, 2025, 4:40 PM EDT - 1 year ago

Apogee Therapeutics Transcript: Bank of America 2025 Healthcare Conference

May 12, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Investor Presentation

May 12, 2025, 6:05 AM EDT - 1 year ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

May 12, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

May 12, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Quarterly report: Q1 2025

May 12, 2025, 6:00 AM EDT - 1 year ago

Apogee Therapeutics Earnings release: Q1 2025

May 9, 2025, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Slides: Corporate Presentation

May 1, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Apogee Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 8:40 AM EDT - 1 year ago

Apogee Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 4, 2025, 2:30 PM EST - 1 year ago

Apogee Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:30 AM EST - 1 year ago

Apogee Therapeutics Transcript: Study Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Apogee Therapeutics Press release: Study Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Apogee Therapeutics Slides: Study Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Apogee Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Apogee Therapeutics Annual report: Q4 2024

Mar 3, 2025, 6:05 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Mar 3, 2025, 6:00 AM EST - 1 year ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Feb 28, 2025, 4:00 PM EST - 1 year ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Feb 25, 2025, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

MorganHoratio Jul. 2 at 10:34 PM

1 · Reply

TradeSun Jul. 2 at 1:25 PM

0 · Reply

Quantumup Jul. 1 at 1:37 PM

0 · Reply

JFais Jun. 30 at 3:24 PM

1 · Reply

lostifm Jun. 27 at 7:17 AM

$EVMN tic toc 👀 Loaded shares today. Especially with $APGE buyout, positive results will really skyrocket

0 · Reply

bden21 Jun. 27 at 5:40 AM

$APGE so, no bidding wars!!! Is it possible we get a better offer?

0 · Reply

topstockalerts Jun. 27 at 2:15 AM

0 · Reply

SellasgpsCurativeBAT11 Jun. 26 at 3:49 PM

0 · Reply

EluyE Jun. 25 at 3:39 PM

$APGE This stock is the luckiest on the street..Had the deal happened just a couple of days ago later that it did, it would have been sub 100 for sure!! Can’t they renegotiate this deal?

1 · Reply

OnlyFibs Jun. 24 at 8:16 PM

RECAP 6/24 +Pos Comments: $PAC + Itau BBA $MHO + Freedom Broker RECAP 6/24 -Neg Comments: $APGE - Stifel $MCHP - J capital

0 · Reply

OpenOutcrier Jun. 24 at 7:59 PM

RECAP 6/24 +Pos Comments: $PAC + Itau BBA $MHO + Freedom Broker RECAP 6/24 -Neg Comments: $APGE - Stifel $MCHP - J capital Live Breaking trading news www.openoutcrier.com

0 · Reply

Lanuchbox Jun. 24 at 12:28 PM

$APGE

0 · Reply

anachartanalyst Jun. 24 at 10:01 AM

$APGE https://anachart.com/wp-content/uploads/2026/06/1782295269_soc-img.jpg

0 · Reply

EluyE Jun. 23 at 4:39 PM

$APGE

0 · Reply

BigStockJohnson Jun. 23 at 3:08 PM

$APGE this one just might get a secondary unsolicited buyout offer from another big player 🤑

0 · Reply

Quantumup Jun. 23 at 1:22 PM

Canaccord⬆️ $ABBV-$273, reit Buy/said: ABBV's acquisition of $APGE for ~$10.1B net makes very good strategic sense adding a potential mega-blockbuster Immunology asset for AD/asthma that should be a major growth driver in the next decade. KYMR CRVS ORKA REGN - SNY $LLY Here's what else Canaccord Genuity had to say: https://x.com/Quantumup1/status/2069410413242921075?s=20

0 · Reply

Lanuchbox Jun. 23 at 12:22 PM

$APGE

0 · Reply

Quantumup Jun. 23 at 12:12 PM

H.C. Wainwright reiterated $ORKA Buy-$120 UCBJY JNJ - PTGX ALMS TAK H.C. Wainwright commented on y'day's $APGE and $ABBV M&A deal, pointing to Apogee's similarity to Oruka, as it was incepted by privately-held Paragon Therapeutics, and additionally said: In our view, Oruka and Apogee have many points of commonality, including a focus on I&I (particularly inflammatory skin diseases) and the intent to advance investigational agents with best-in-disease potential. We reiterate our Buy rating and 12-month price target of $120 per share.

0 · Reply

LewisDaKat Jun. 23 at 10:30 AM

$APGE Neutral Recommendation Issued On APGE By UBS https://marketwirenews.com/stock/apge/news/neutral-recommendation-issued-on-apge-by-ubs-5648788100441611.html?utm_source=stocktwits

0 · Reply

EluyE Jun. 23 at 7:59 AM

$APGE open @110 or 140?

0 · Reply

mikesterz7 Jun. 23 at 6:45 AM

$APGE Apogee Therapeutics shares surged to a record high of $133 after AbbVie agreed to acquire the company in a $10.9 billion all-cash deal.

0 · Reply

Stocks_and_Stacks Jun. 23 at 6:06 AM

🚀 Bulls stacking wins on Monday June 22 with biotech catalysts, small-cap volume surges, and AI infrastructure momentum! 🐂📈 First off 😎 who’s all up late studying charts and getting ready for tomorrow? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp, bulls! Huge congrats to everyone riding these top 5 movers today. $APGE +46.7% – Apogee Therapeutics surging on positive biotech pipeline news and strong institutional buying. $DFTX +49.8% – Definium Therapeutics exploding on clinical catalyst and speculative small-cap momentum. $SMCI + momentum – Super Micro Computer lifting on new AI data center blueprint with Nvidia tech. $ORKA +18% – Oruka Therapeutics climbing on healthcare sector rotation and volume surge. $HQ +20% – Horizon Quantum Holdings gaining on quantum/AI interest and breakout action. Solid start to the week with resilience, bulls 😎 #TopMovers #BullMarket #Stocks #BangerAlerts #BiotechRally

1 · Reply

Market Cap	8.23B
Revenue (ttm)	0.00
Net Income (ttm)	-255.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,998,800
Avg Vol	2,867,036
Day's Range	N/A - N/A
Shares Out	61.90M
Stochastic %K	33%
Beta	0.32
Analysts	Sell
Price Target	$127.59